Neuronetics Inc. STIM shares soared 41.08% to $2.06 in after-hours trading on Tuesday following preliminary fourth-quarter ...

Why Neuronetics is back on investor radars Neuronetics (STIM) is drawing fresh attention after reporting preliminary fourth quarter 2025 revenue of US$41.8 million and generating positive operating ...

As of Wednesday, February 11, Neuronetics, Inc.’s STIM share price has surged by 21.58%, which has investors questioning if ...

As of Thursday, February 12, Neuronetics, Inc.’s STIM share price has dipped by 8.89%, which has investors questioning if this is right time to buy.

All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth ...

Detailed price information for Neuronetics Inc (STIM-Q) from The Globe and Mail including charting and trades.

Neuronetics, Inc. (NASDAQ:STIM) shareholders should be happy to see the share price up 28% in the last week. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. Five years ...

Neuronetics is currently facing challenges from increased competition and a difficult macro environment, which is impacting growth and profitability. While market conditions appear to have stabilized ...

Neuronetics, Inc., a medical technology company focused on mental health, has announced key updates regarding its NeuroStar therapy. The company will be a Silver Sponsor at the 13th Annual Clinical ...

MALVERN, Pa., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve ...

MALVERN, Pa. and TORONTO, Oct. 4, 2024 /PRNewswire/ - Neuronetics, Inc. (NASDAQ: STIM) ("Neuronetics") and Greenbrook TMS Inc. (OTCMKTS: GBNHF) ("Greenbrook") today ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Neuronetics, which has 203 ...